TREATMENT OUTCOME OF CHEMOTHERAPY AND ANTIRETROVIRAL THERAPY AND COTRIMOXAZOLE PREVENTIVE THERAPY IN TUBERCULOSIS PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS COINFECTION

Girija Shankar Udgata; Srikanta Dash; SARITA BEHERA; Sasmita Meher; Ananya Udgata; Hota S

doi:10.22159/ajpcr.2023.v16i7.48370

Authors

Girija Shankar Udgata Department of Pulmonary Medicine, BBMCH, Balangir, Odisha, India.
Srikanta Dash Department of Pulmonary Medicine, BBMCH, Balangir, Odisha, India.
SARITA BEHERA Department of Medicine, BBMCH, Balangir, Odisha, India. https://orcid.org/0000-0002-6403-4926
Sasmita Meher Department of Pulmonary Medicine, BBMCH, Balangir, Odisha, India.
Ananya Udgata Department of Pharmacology, BBMCH, Balangir, Odisha, India.
Hota S Department of Ophthalmology, BBMCH, Balangir, Odisha, India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i7.48370

Keywords:

Tuberculosis, Human immunodeficiency virus, Tuberculosis and human immunodeficiency virus coinfection, Antiretroviral therapy, Cotrimoxazole preventive therapy

Abstract

Objective: In developing countries like India, the fatality rate of tuberculosis (TB) coinfected with human immunodeficiency virus (HIV) is still at high rate and imposes significant challenge among the physicians. The present study was conducted to evaluate management outcomes of combined antiretroviral therapy (ART) and chemotherapy or cotrimoxazole preventive therapy (CPT) in TB/HIV co-infected patients.

Methods: The study was conducted on 3512 confirmed TB patients who were treated with ART and CPT therapy. Out of these, HIV positive was 58 cases and HIV negative was 3414 cases. HIV cases the algorithm KHB- Statpak- Unigold were used. Patient started CPT.

Results: Percentage of TB and HIV coinfection was 58 and the coinfection was greater in 20–40-year age groups and 2 times higher in PTB sputum-positive cases. Among the extrapulmonary TB cases, 76% took CPT + ART. The treatment success was 86%.

Conclusion: Thus, CPT therapy must be established in all centers and compulsory HIV screening must be implicated throughout the country.

Downloads

Download data is not yet available.

References

Do Prado TN, Rajan JV, Miranda AE, Dias ED, Cosme LB, Possuelo LG, et al. Clinical and epidemiological characteristics associated with unfavorable tuberculosis treatment outcomes in TB-HIV co-infected patients in Brazil: A hierarchical polytomous analysis. Braz J Infect Dis 2017;21:162-70. doi: 10.1016/j.bjid.2016.11.006, PMID 27936379

Tiberi S, Carvalho AC, Sulis G, Vaghela D, Rendon A, Mello FC, et al. The cursed duet today: Tuberculosis and HIV-coinfection. Presse Med 2017;46:e23-39. doi: 10.1016/j.lpm.2017.01.017, PMID 28256380

World Health Organization. WHO Global Tuberculosis Report 2016. Geneva, Switzerland: World Health Organization; 2016. p. 214.

World Health Organization. Global TB Report 2020. Geneva, Switzerland: World Health Organization; 2020.

Ansa GA, Sifa JS. Tuberculosis and HIV integration in sub-Saharan Africa. Asian Pac J Trop Dis 2015;5:841-9. doi: 10.1016/S2222- 1808(15)60927-6

World Health Organization. Ending TB in the South-East Asia Region: Broad Strategic Plan 2016-2020. Geneva, Switzerland: World Health Organization; 2016.

World Health Organization. A Situational Analysis of Programmatic Management of TB Preventive Treatment in the WHO South-East Asia Region. Geneva, Switzerland: World Health Organization; 2020.

Jaiswal RK, Srivastav S, Mahajan H. Socio demographic profile of TB-HIV co-infected patients in Bundelkhand Region, Uttar-Pradesh. Natl J Med Res 2012;2:149-51.

Marfatia YS, Sharma A, Modi M. Overview of HIV/AIDS in India. Indian J Sex Transm Dis AIDS 2007;28:1-5. doi: 10.4103/0253- 7184.35702

Narain JP, Lo YR. Epidemiology of HIV-TB in Asia. Indian J Med Res 2004;120:277-89. PMID 15520482

Londhey VA. HIV and tuberculosis--a “cursed duo” in the HAART era. J Assoc Physicians India 2009;57:681-2. PMID 20329423

Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Marjani M, Mansouri D. Treatment outcome and mortality: Their predictors among HIV/TB co-infected patients from Iran. Int J Mycobacteriol 2012;1:82- 6. doi: 10.1016/j.ijmyco.2012.05.002, PMID 26787060

Smith JP, Gandhi NR, Shah NS, Mlisana K, Moodley P, Johnson BA, et al. The impact of concurrent antiretroviral therapy and MDR-TB treatment on adverse events. J Acquir Immune Defic Syndr 2020;83:47-55. doi: 10.1097/QAI.0000000000002190, PMID 31809360

Stephens F, Gandhi NR, Brust JC, Mlisana K, Moodley P, Allana S, et al. Treatment adherence among persons receiving concurrent multidrug-resistant tuberculosis and HIV treatment in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2019;82:124-30. doi: 10.1097/QAI.0000000000002120, PMID 31513073

Gebremariam G, Asmamaw G, Hussen M, Hailemariam MZ, Asegu D, Astatkie A, et al. Impact of HIV status on treatment outcome of tuberculosis patients registered at Arsi Negele health center, Southern Ethiopia: A six year retrospective study. PLoS One 2016;11:e0153239. doi: 10.1371/journal.pone.0153239, PMID 27096159

Kamath R, Sharma V, Pattanshetty S, Hegde MB, Chandrasekaran V. HIV-TB coinfection: Clinico-epidemiological determinants at an antiretroviral therapy center in Southern India. Lung India 2013;30:302-6. doi: 10.4103/0970-2113.120605, PMID 24339487

Vijay S, Kumar P, Chauhan LS, Rao SV, Vaidyanathan P. Treatment outcome and mortality at one and half year follow-up of HIV infected TB patients under TB control programme in a district of South India. PLoS One 2011;6:e21008. doi: 10.1371/journal.pone.0021008, PMID 21814542

Sileshi B, Deyessa N, Girma B, Melese M, Suarez P. Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: A retrospective cohort study. BMC Infect Dis 2013;13:297. doi: 10.1186/1471-2334-13-297, PMID 23815342

Alobu I, Oshi SN, Oshi DC, Ukwaja KN. Risk factors of treatment default and death among tuberculosis patients in a resource-limited setting. Asian Pac J Trop Med 2014;7:977-84. doi: 10.1016/S1995- 7645(14)60172-3, PMID 25479627

Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50:148-52. doi: 10.1097/QAI.0b013e31819367e7, PMID 19131895

Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, et al. Cotrimoxazole prophylaxis and antiretroviral therapy: An observational cohort study in China. Bull World Health Organ 2015;93:152-60. doi: 10.2471/ BLT.14.142745, PMID 25838611

Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, et al. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: Results from the Treat Asia HIV observational database. J Int AIDS Soc 2012;15:1. doi: 10.1186/1758-2652-15-1, PMID 22281054